Celgene Corp. (CELG)

95.44
0.92 0.95
NASDAQ : Health Technology
Prev Close 96.36
Open 95.95
Day Low/High 95.37 / 96.27
52 Wk Low/High 58.59 / 97.07
Volume 3.04M
Avg Volume 8.73M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 67.88B
EPS 5.70
P/E Ratio 14.69
Div & Yield N.A. (N.A)

Your Pinch Hitter for Today, Bret Jensen!

As always, it is good to be sitting in for Doug Kass on the Daily Diary over the next two days. There is lots to talk about. We have a flood of first-quarter earnings results that we can discuss. I will be looking to see if quarterly numbers from bi...

The Good, the Bad and the Ugly (Mid-Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...

Takeaways and Observations (Early Edition)

'Til April in Paris, chestnuts in blossom Holiday tables under the trees April in Paris, this is a feeling That no one can ever reprise - April in Paris, Vernon Duke and Yip Harburg - (rare video with Ella Fitzgerald!)  The market gapped higher and ...

Intermediate Trade: Celgene

Intermediate Trade: Celgene

I prefer a very short-term, out-of-the-money vertical call spread expiring in May.

Momentum Is Fading

Momentum Is Fading

Forget financials, stick to steady growers.

The Good, the Bad and the Ugly (EarlyAfternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I want to spend some time with my family right after the close. So let's move...

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Takeaways And Observations

For the first time in six years the DJIA fell for the eighth consecutive day. That said the Nasdaq has risen in ten of the last thirteen trading sessions as Donald Trump may be making volatility and uncertainty great again. (For that divergence and ...

Takeaways & Observations

Risk happens fast.  Most don't short and shouldn't short -- it's a game that requires volumes of risk control.  However, I would continue to maintain well above-average cash positions.  Today was not a benign event, in my view.  Nor was it likely a ...

Celgene Has Cure for Market Blues

Celgene Has Cure for Market Blues

Strong biotech stock has surged since November and is close to all-time highs.

Cramer: The Airlines and Health-Care Names Are Really Soaring

Cramer: The Airlines and Health-Care Names Are Really Soaring

This reversal has been incredible to watch.

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

Research firm Credit Suisse has put together a list of 140 "top ideas" covered by their analysts.

Health Care Putting in a Base

Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...

Takeaways & Observations

This is a great invite, "Wall Street Goes to Washington," in which legendary journalist Michael Wolff will sit down with my pal, The Mooch! And it's free!  Happy eighth anniversary, Mr. Market. My Generational Low call on The Kudlow Report was the b...

Takeaways and Observations

  "Wishin' and hopin' And thinkin' and prayin'..."  -- Dusty Springfield, Wishin' and Hopin'  The gap from last week's presidential speech was filled this afternoon.  I am more negative than most and more negative than I have been in a while.  Liter...

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Go With Allergan, Celgene and 'Big Mo'

Go With Allergan, Celgene and 'Big Mo'

These two large-cap drug giants should be core parts of any well-diversified portfolio.

Takeaways and Observations

  Every single market indicator I look at is overbought.  But it's likely that shorts and underperformers are buoying stocks.  Some are at the most overbought in decades.  The bond market is clearly not as sanguine on economic growth/corporate profi...

Takeaways and Observations

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters.  I covered last evening's Procter & Gamble short for a profit.  "For Traders Only."...

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Takeaways and Observations

  Fear and doubt seem to have abandoned Wall Street.  Dr. Hussman, while very much perma-bear, makes some good points in his weekly market commentary. See boldface.  As does my pal Sir Mark Grant on CNBC's Squawk Box.  I have reduced my large SPRD G...

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Trump Investing: Listen, Don't Overreact

Trump Investing: Listen, Don't Overreact

Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.

My Takeaways and Observations

We are likely in a Trump-centric investment world in 2017.   My theme that the president will make market volatility and uncertainty great again, continues.    Consider the contrary, Part Deux.    Mo' gold and I will accumulate under any weakness go...

My Takeaways and Observations

Risk happens fast.    Is the presidential honeymoon over? One of the 10 questions I asked myself today.    "The Return of the Orange Swan?"    Has Boca Biff done it again? Another top call?    Ten questions. In particular, read my comments on Steve ...

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

My Takeaways and Observations

"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...

Three Health-Care Growth Plays

Three Health-Care Growth Plays

Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.

My Takeaways and Observations

The market pushed back presumably after it digested the inaugural speech and absorbed the marches around the world.   I don't believe the new president will be market and economy friendly.    The reflation trade is in question today.  And I remain b...